In this articleBMYJNJJonathan Raa | Nurphoto | Getty ImagesThink a friend or colleague should be getting this newsletter? Share this link with them to sign up.Hi folks! Two competing cell therapies from Bristol Myers Squibb and Johnson & Johnson both got good news from the Food and Drug Administration on Friday. But J&J's drug is walking away with a notable edge over its rival.The FDA expanded the approvals of both therapies, allowing patients to use them as earlier lines of treatment for a type of blood ca ...